Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire MYR GmbH for approximately €1.5 billion on December 9, 2020. As per the terms, Gilead will pay a consideration of €1.15 billion in cash upon closing of the transaction, plus a potential future milestone payment of up to €300 million upon U.S. FDA approval (both payments subject to customary adjustments). The transaction is expected to be funded entirely with existing cash. Under the transaction, approximately 35 employees based mostly in Germany and France will be joining Gilead. The transaction is subject to regulatory approval, expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of merger control approvals in certain European jurisdictions and other customary closing conditions. The transaction is expected to close in the first quarter of 2021. After the closing, in addition to enhancing Gilead's revenue growth, the acquisition of MYR is expected to be neutral to non-GAAP EPS in the first two years after close and moderately accretive thereafter. Goldman Sachs & Co. LLC acted as the financial advisor to Gilead. UBS Europe SE acted as the financial advisor to MYR. Christopher Dillon and Dirk Oberbracht of Gibson, Dunn & Crutcher, Mayer Brown LLP, and Flick Gocke Schaumburg acted as the legal advisors to Gilead. Jochen Dieselhorst, Stephanie Hundertmark, Mary Lehner, Frank Röhling and Christian Ruoff of Freshfields Bruckhaus Deringer Rechtsanwälte Steuerberater PartG mbB acted as the legal advisor to MYR.